Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients: US Healthcare System Perspective

Author： Delea Thomas E.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.4, 2007-01, pp. : 329-342

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Iron-Chelating Therapies in a Transfusion-Dependent Thalassaemia Population in Thailand: A Cost-Effectiveness Study

By Luangasanatip Nantasit   Chaiyakunapruk Nathorn   Upakdee Nilawan   Wong Peerapon  

Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. : 493-505

Adis International

Access to resources Recommend Favorite

Conversion from Standard Opioid Therapy to Once-daily Oral Extended-release Hydromorphone in Patients with Chronic Cancer Pain

By Wallace M   Rauck RL   Moulin D   Thipphawong J   Khanna S   Tudor IC  

The Journal of International Medical Research, Vol. 36, Iss. 2, 2008-03 ,pp. : 343-352

Field House Publishing

Access to resources Recommend Favorite

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

By Cappellini MD   Taher A  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2391-2402

Informa Healthcare

Access to resources Recommend Favorite

Age-Dependent Therapeutic Effects of Once-Daily Molsidomine Used as an Add-On Treatment in Patients with Stable Angina pectoris

By  

Heart Drug, Vol. 4, Iss. 4, 2004-12 ,pp. : 184-189

Karger

Access to resources Recommend Favorite

Oral deferasirox may be an effective iron chelator in patients with thalassaemia and transfusional iron overload

By  

Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite